Mirum Pharmaceuticals, Inc. — Cyborg Score 8/10

Strong
Biopharmaceuticals - Rare & Orphan Diseases

Strategic Profile

The company achieved 2024 revenue of $336.89 million, representing 80.76% growth compared to prior year. Mirum recently completed the Bluejay Acquisition, expanding its liver disease portfolio. Analysts hold a "Strong Buy" rating with a 12-month price target of $102.64.

Cyborg Score Rationale

Revenue growth of 81% YoY demonstrates strong commercial execution and market traction. Patient identification expansion and international growth are driving margins, while late-stage pipeline programs support future diversification and earnings acceleration. Strategic acquisition activity strengthens competitive positioning in rare liver diseases.

Top Insights

  • Strong revenue growth of 81% YoY in 2024 demonstrates effective commercialization and market adoption
  • Recent Bluejay Therapeutics acquisition adds hepatitis delta virus treatment to portfolio, expanding addressable market
  • International expansion providing additional revenue growth runway beyond U.S. market
  • Approaching profitability with net losses declining 46% YoY as commercial scale improves

Named Competitors

  • Rhythm Pharmaceuticals — Rare disease company focused on obesity and metabolic disorders
  • Travere Therapeutics — Rare kidney disease specialist pharmaceutical company
  • Tarsus Pharmaceuticals — Rare ophthalmology and dermatology disease medicines
  • Apellis Pharmaceuticals — Rare complement-mediated disease therapies

Recent Developments

  • (January 2026) Completed acquisition of Bluejay Therapeutics, adding late-stage hepatitis delta virus treatment
  • (January 2026) Price target raised to $115 from $95 at TD Cowen
  • (December 2025) Released strong 2025 sales results and 2026 revenue guidance of $630M-$650M
  • (January 2026) Health Canada authorized LIVMARLI tablet formulation for Alagille Syndrome and PFIC

Open the full interactive Mirum Pharmaceuticals, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →